{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:01:41Z","timestamp":1791309701040,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40121-025-01275-3","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:23:34Z","timestamp":1765383814000},"page":"477-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4997-3121","authenticated-orcid":false,"given":"Zinan","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athar Ali","family":"Tajik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Toksvig","family":"Klitkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleana","family":"Tsoumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Owusu-Edusei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"1275_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050420","author":"C Scelfo","year":"2021","unstructured":"Scelfo C, Menzella F, Fontana M, Ghidoni G, Galeone C, Facciolongo NC. Pneumonia and invasive pneumococcal diseases: the role of pneumococcal conjugate vaccine in the era of multi-drug resistance. Vaccines (Basel). 2021. https:\/\/doi.org\/10.3390\/vaccines9050420.","journal-title":"Vaccines (Basel)"},{"key":"1275_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107023","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Cossrow N, Yu KC, Ye G, White M, Gupta V. Clinical and economic burden of invasive pneumococcal disease and noninvasive all-cause pneumonia in hospitalized US adults: a multicenter analysis from 2015 to 2020. Int J Infect Dis. 2024. https:\/\/doi.org\/10.1016\/j.ijid.2024.107023.","journal-title":"Int J Infect Dis"},{"key":"1275_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.12.365","author":"H Fukuda","year":"2022","unstructured":"Fukuda H, Onizuka H, Nishimura N, Kiyohara K. Risk factors for pneumococcal disease in persons with chronic medical conditions: results from the LIFE study. Int J Infect Dis. 2022. https:\/\/doi.org\/10.1016\/j.ijid.2021.12.365.","journal-title":"Int J Infect Dis"},{"key":"1275_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-206780","author":"A Torres","year":"2015","unstructured":"Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: Table\u00a01. Thorax. 2015. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-206780.","journal-title":"Thorax"},{"key":"1275_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.03.057","author":"P Magali","year":"2024","unstructured":"Magali P, Sophie M, Arnaud B, Pol L, Den Bulcke Julie V, Jonathan B. Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings. Vaccine. 2024. https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.057.","journal-title":"Vaccine"},{"key":"1275_CR6","unstructured":"European Centre for Disease Prevention and Control. Invasive pneumococcal disease - Annual Epidemiological Report for 2022. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/invasive-pneumococcal-disease-annual-epidemiological-report-2022; 2025. Accessed 2 Apr 2025."},{"key":"1275_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9081774","author":"BA Winje","year":"2021","unstructured":"Winje BA, Vestrheim DF, White RA, Steens A. The risk of invasive pneumococcal disease differs between risk groups in Norway following widespread use of the 13-valent pneumococcal vaccine in children. Microorganisms. 2021. https:\/\/doi.org\/10.3390\/microorganisms9081774.","journal-title":"Microorganisms"},{"key":"1275_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.032","author":"A Steens","year":"2013","unstructured":"Steens A, Bergsaker MA, Aaberge IS, Ronning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013. https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.032.","journal-title":"Vaccine"},{"key":"1275_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4754-0","author":"A Lovlie","year":"2020","unstructured":"Lovlie A, Vestrheim DF, Aaberge IS, Steens A. Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13. BMC Infect Dis. 2020. https:\/\/doi.org\/10.1186\/s12879-019-4754-0.","journal-title":"BMC Infect Dis"},{"key":"1275_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2469424","author":"H Maeda","year":"2025","unstructured":"Maeda H, Morimoto K. Global distribution and characteristics of pneumococcal serotypes in adults. Hum Vaccin Immunother. 2025. https:\/\/doi.org\/10.1080\/21645515.2025.2469424.","journal-title":"Hum Vaccin Immunother"},{"key":"1275_CR11","unstructured":"Norwegian Institute of Public Health. Pneumococcal vaccine for risk groups. 2023. https:\/\/www.fhi.no\/en\/va\/vaccines-for-adults\/pneumococcal-vaccine-for-risk-groups\/. Accessed 29 Oct 2024."},{"key":"1275_CR12","unstructured":"Norwegian Institute of Public Health. Pneumococcal vaccine \u2013 a guide for healthcare professionals. 2025. https:\/\/www.fhi.no\/va\/vaksinasjonshandboka\/vaksiner-mot-de-enkelte-sykdommene\/pneumokokkvaksinasjon\/?term. Accessed 23 July 2025."},{"key":"1275_CR13","unstructured":"Norwegian Institute of Public Health. Vaccines for adults. https:\/\/www.fhi.no\/en\/va\/vaccines-for-adults\/#:~:text=The%20programme%20will%20start%20offering,a%20vaccine%20against%20pneumococcal%20disease. Accessed 5 Nov 2025."},{"key":"1275_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2101333","author":"LS Nymark","year":"2022","unstructured":"Nymark LS, Dag Berild J, Lyngstad TM, et al. Cost-utility analysis of the universal pneumococcal vaccination programme for older adults in Norway. Hum Vaccin Immunother. 2022. https:\/\/doi.org\/10.1080\/21645515.2022.2101333.","journal-title":"Hum Vaccin Immunother"},{"key":"1275_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01396-3","author":"V Eldholm","year":"2024","unstructured":"Eldholm V, Osnes MN, Bjornstad ML, Straume D, Gladstone RA. A genome-based survey of invasive pneumococci in Norway over four decades reveals lineage-specific responses to vaccination. Genome Med. 2024. https:\/\/doi.org\/10.1186\/s13073-024-01396-3.","journal-title":"Genome Med"},{"key":"1275_CR16","unstructured":"Norwegian Institute of Public Health. Norwegian Immunisation Registry SYSVAK. Data delivered to MSD Norway for the year\u00a02023. https:\/\/www.fhi.no\/en\/va\/norwegian-immunisation-registry-sysvak\/. Accessed 5 Nov 2025."},{"key":"1275_CR17","unstructured":"Norwegian Institute of Public Health. Norwegian Surveillance System for Communicable Diseases Data delivered to MSD Norway for the years\u00a02021\u20132023. https:\/\/www.fhi.no\/en\/ou\/msis\/. Accessed 5 Nov 2025."},{"key":"1275_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-00988-1","author":"Z Yi","year":"2024","unstructured":"Yi Z, Johnson KD, Owusu-Edusei K. Lifetime health and economic burden of invasive pneumococcal diseases attributable to V116 serotypes among adults in the United States. Infect Dis Ther. 2024. https:\/\/doi.org\/10.1007\/s40121-024-00988-1.","journal-title":"Infect Dis Ther"},{"key":"1275_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01067-1","author":"Z Yi","year":"2024","unstructured":"Yi Z, Owusu-Edusei K, Elbasha E. Cost-effectiveness analysis of the use of V116, a 21-valent pneumococcal conjugate vaccine, in vaccine-naive adults aged >\/= 65\u00a0years in the United States. Infect Dis Ther. 2024. https:\/\/doi.org\/10.1007\/s40121-024-01067-1.","journal-title":"Infect Dis Ther"},{"key":"1275_CR20","unstructured":"Norwegian Medical Products Agency. Submission Guidelines For Single Technology Assessment of\nMedical Products 2024. Available from: https:\/\/www.dmp.no\/globalassets\/documents\/offentlig-finansiering-og-pris\/dokumentasjon-til-metodevurdering\/submission-guidelines-november-2025.pdf. Accessed 3 Apr 2025."},{"key":"1275_CR21","unstructured":"Statistics Norway. Population by sex and one-year age groups (M), 1986\u20132024. https:\/\/www.ssb.no\/en\/statbank\/table\/07459\/; 2024. Accessed 29 Oct 2024."},{"key":"1275_CR22","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Disease. https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx. Accessed 12 July 2024."},{"key":"1275_CR23","unstructured":"Norwegian Institute of Public Health. Data from the Norwegian Surveillance System for Communicable Diseases delivered to MSD Norway. 2024. https:\/\/www.fhi.no\/en\/ou\/msis\/. Accessed 5 Nov 2025."},{"key":"1275_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30306-0","author":"T Shiri","year":"2017","unstructured":"Shiri T, Datta S, Madan J, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017. https:\/\/doi.org\/10.1016\/S2214-109X(16)30306-0.","journal-title":"Lancet Glob Health"},{"key":"1275_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287378","author":"A Palmborg","year":"2023","unstructured":"Palmborg A, Skovdal M, Molden T, Ahman H, Chen L, Banefelt J. Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination-a longitudinal study over 10\u00a0years based on public surveillance data in the Nordics. PLoS ONE. 2023. https:\/\/doi.org\/10.1371\/journal.pone.0287378.","journal-title":"PLoS ONE"},{"key":"1275_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.052","author":"C Chen","year":"2018","unstructured":"Chen C, Wood JG, Beutels P, et al. The role of timeliness in the cost-effectiveness of older adult vaccination: a case study of pneumococcal conjugate vaccine in Australia. Vaccine. 2018. https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.052.","journal-title":"Vaccine"},{"key":"1275_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3651-0","author":"C Stoecker","year":"2016","unstructured":"Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50\u00a0years and older in the United States. J Gen Intern Med. 2016. https:\/\/doi.org\/10.1007\/s11606-016-3651-0.","journal-title":"J Gen Intern Med"},{"key":"1275_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy800","author":"SI Pelton","year":"2019","unstructured":"Pelton SI, Bornheimer R, Doroff R, Shea KM, Sato R, Weycker D. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciy800.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1275_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jinf.2010.04.008","volume":"61","author":"M Jit","year":"2010","unstructured":"Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect. 2010;61(2):114. https:\/\/doi.org\/10.1016\/j.jinf.2010.04.008.","journal-title":"J Infect"},{"key":"1275_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.088","author":"SS Huang","year":"2011","unstructured":"Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011. https:\/\/doi.org\/10.1016\/j.vaccine.2011.02.088.","journal-title":"Vaccine"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01275-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01275-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01275-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:27:12Z","timestamp":1769678832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01275-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01275-3","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zinan Yi and Kwame Owusu-Edusei are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. S\u00f8ren Toksvig Klitkou and Athar Ali Tajik are employees of MSD Norway. Eleana Tsoumani is an employee of MSD Greece. All authors may hold stock or stock options in Merck & Co., Inc., Rahway, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As this was a modeling study using de-identified data as model inputs, ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}